


# Acute Pain Management in Patients on Buprenorphine (Bup) Treatment for Opioid Use Disorder

**Emergency Department / Critical Care** 



#### Promote calm and comfort

**Anxiety, fear, depression are common**: Instill sense of control, provide education on self-management techniques such as mindfulness meditation. Reduce noise, uncertainty, confusion.

Positioning, splinting, and physical comfort should be maximized. Minimize unnecessary NPO status.

### TREAT UNPLEASANT SYMPTOMS:

Diphenhydramine 25-50mg PO q8h prn insomnia/anxiety

Tizanidine 2-4mg q6h prn muscle spasms

Ondansetron 4mg PO q6h prn nausea

Trazadone 50mg PO qhs prn insomnia

Melatonin 3mg PO qhs prn insomnia

Lorazepam 0.5-1mg PO prn anxiety

Antipsychotics prn psychotic disorder symptom control

Nicotine replacement prn tobacco dependence

#### **Regional Anesthesia**

**Peripheral nerve blocks:** superficial cervical plexus, brachial plexus, radial/median/ulnar, PECS, erratus plane, TAP, femoral, sciatic, posterior tibial.

Spinal and Epidural anesthesia

# **Acetaminophen and NSAIDs**

**Acetaminophen** and **NSAIDs**, when not contrainidicated, should are the foundation of a multimodal analgesic strategy.

### **Gabapentinoids**

In opioid depenent patients, the calcium channel inhibitors, gabapentin and pregabalin reduce postoperative pain and reduce opioid consumption. Gabapentin 300-600mg PO TID.

# Alpha-2 agonists

Clonidine and Dexmedetomidine are anxiolytic and analgesic with significant opioid sparing affects. e.g. **Clonidine** 0.1-0.3mg PO q6-8h prn pain or anxiety (NTE 1.2mg/day, hold if BP <100/70).

# **Ketamine & Magnesium (NMDAR antagonists)**

**Ketamine** is the most potent non-opioid analgesic for opioid tolerant patients. A brief infusion of 0.3mg/kg IV over 15min is followed by 0.3-1mg/kg/hr as needed.

**Magnesium** is also an NMDAR with analgesic and opioid sparing effect. eg. 30-50mg/kg bolus followed by 10-mg/kg/hr.

#### IV Lidocaine (Na channel antagonist)

Opioid sparing analgesic. A bolus of 1-1.5mg/kg is followed by 1.5-3 mg/kg/h. Contraindications include cardiac dysrthymias. Must monitor serum levels after 24hrs.

### **High Affinity Full agonist Opioids**

Hydromorphone, fentnayl, and sufentanil can be added to maintenance Bup to provide synergistic analgesia. Titrate to analgesia and side effects. This will NOT cause withdrawal.

# **Additional Bup**

There is no clinical ceiling on Bup analgesia. SL Bup can be given as frequently as q2h. IV Bup is a potent analgesic start at 0.3mg IV and titrate as needed. At higher doses respiratory depression does occur.

Guidelines are options for multimodal analgesic therapy. Use clinical judgement and avoid use if contraindicated.

The CA Bridge Program disseminates resources developed by an interdisciplinary team based on published evidence and medical expertise. These resources are not a substitute for clinical judgment or medical advice. Adherence to the guidance in these resources will not ensure successful patient treatments. Current best practices may change. Providers are responsible for assessing the care and needs of individual patients.

# **REFERENCES**

# Acute Pain Management in Patients on Buprenorphine (Bup) Treatment for OUD



Alford D, Compton P, Samet J. Acute pain management for patients receiving maintenance methadone or buprenorphine therapy. *Ann Int Med.* 2006; 144(2):127-134.

Aurora Naa-Afoley Quaye, Yi Zhang, Perioperative Management of Buprenorphine: Solving the Conundrum, *Pain Medicine*. 2019; 20,(7):1395–1408.

Buvanendran A, Kroin JS. Multimodal analgesia for controlling acute postoperative pain. Curr Opin Anaesthesiol. 2009; 22(5):588-93.

Elvir-Lazo OL, White PF. The role of multimodal analgesia in pain management after ambulatory surgery. *Curr Opin Anaesthesiol.* 2010;23(6):697-703.

Fabrício T M, Mariana C R, Jordana A A, Luíse A C. Systemic Lidocaine for Perioperative Analgesia: A Literature Review. *J Anest & Inten Care Med.* 2015;1(1): 555551.

Fitzpatrick BM, Mullins ME. Intravenous lidocaine for acute pain: an evidence-based clinical update. *Clin Exp Emerg Med.* 2016; 3(2): 105–108.

Goel A, Azargive S, Weissman JS, et al. Perioperative pain and addiction interdisciplinary network (PAIN) clinical practice advisory for perioperative management of buprenorphine: results of a modified Delphi process. *Br J Anaesth*. 2019;123(2):e333-e342.

Hansen LE, Stone GL, Matson CA. Total joint arthroplasty in patients taking methadone or buprenorphine/naloxone preoperatively for prior heroin addiction: a prospective matched cohort study. J Arthroplasty. 2016;31(8):1698-701.

Harrison TK, Kornfeld H, Aggarwal AK, et al. Perioperative considerations for the patient with opioid use disorder on buprenorphine, methadone or naltrexone maintenance therapy. *Anesthesia Clin.* 2018;36(3):345-359

Kranke P. Jokinen J, Pace NL, et al. Continuous intravenous perioperative lidocaine infusion for postoperative pain and recovery. Cochrane Database Syst Rev. 2015;(7):CD009642.

Lawrence A Haber, MD, Triveni DeFries, MD, MPH, Marlene Martin, MD, Things We Do for No Reason™: Discontinuing Buprenorphine When Treating Acute Pain. *J. Hosp. Med* 2019;10;633-635. Published online first August 21, 2019.

Lembke A, Ottestad E, Schmiesing C. Patients Maintained on Buprenorphine for Opioid Use Disorder Should Continue Buprenorphine Through the Perioperative Period. *Pain Medicine*. 2019 Mar 1;20(3):425-428.

Macintyre PE, Russell RA, Usher KA, et al. Pain relief and opioid requirements in the first 24 hour after surgery in patients taking buprenorphine and methadone opioid substitution therapy. *Anaesth Intensive Care*. 2013; 41(2):222-30.

Oifa S, Sydoruk T, White I, et al. Effects of intravenous patient-controlled analgesia with buprenorphine and morphine alone and in combination during the first 12 postoperative hours: a randomized, double-blind, four-arm trial in adults undergoing abdominal surgery. *Clin Ther.* 2009;31(3):527-41.

Radvansky BM, Shah K, Parikh A, Sifonios AN, Le V, Eloy JD. Role of ketamine in acute postoperative pain management: A narrative review. *BioMed Research International*, 2015; 1-10.

Vilkins AI, Bagley SM, Hahn KA, et al. Comparison of post-cesarean section opioid analgesic requirements in women with opioid use disorder treated with methadone or buprenorphine. *J Addict Med.* 2017;11(5):397-401.

Wick EC, Grant MC, Wu CL. Postoperative multimodal analgesia pain management with nonopioid analgesics and techniques, A review. *JAMA Surg.* 2017;152(7):691-697.

CA Bridge disseminates resources developed by an interdisciplinary team based on published evidence and medical expertise. These resources are not a substitute for clinical judgment or medical advice. Adherence to the guidance in these resources will not ensure successful patient treatments. Current best practices may change. Providers are responsible for assessing the care and needs of individual patients.

Documents are periodically updated to reflect the most recent evidence-based research. Materials provided through CA Bridge may be utilized for the sole purpose of providing information for the treatment of substance use disorders. Such materials may be distributed with proper attribution from the California Department of Health Care Services, Public Health Institute, CA Bridge Program. Questions may be submitted via email to <a href="mailto:info@CABridge.org">info@CABridge.org</a>.